ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 90.40% for the 12-month period ending 2021-09-30, per its 10-K filed 2023-11-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2023-11-29
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2020-12-31 was 90.40%, a 0.66% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2019-12-31 was 91.00%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 90.40%, a 1.74% decline from fiscal 2020.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 92.00%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2012 was 100.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2021-09-30 | 90.40% 10-K · filed 2023-11-29 | |||
| 2021-06-30 | 90.40% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 90.40% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 90.40% 10-Q · filed 2022-02-02 | |||
| 2020-09-30 | 92.00% 10-K · filed 2022-11-28 | |||
| 2020-06-30 | 91.90% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 91.80% 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | 91.00% 10-Q · filed 2021-02-04 | |||
| 2012-09-30 | 100.00% 10-K · filed 2014-11-25 | |||
| 2012-06-30 | 100.00% 10-Q · filed 2012-08-13 | |||
| 2012-03-31 | 100.00% 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |